Management of cancer pain: ESMO clinical practice guidelines

Annals of Oncology

Volumn 22, Issue SUPPL. 6, 2011, Pages

  Ripamonti, C I ^a   Bandieri, E ^b   Roila, F ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b AUSL Modena   (Italy)

^c S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CLOMIPRAMINE; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROCODEINE; DULOXETINE; FENTANYL; FLUOXETINE; HYDROMORPHONE; IBUPROFEN; KETOPROFEN; MEFENAMIC ACID; METHADONE; MORPHINE; MORPHINE SULFATE; NALOXONE; NAPROXEN; NICOMORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PLACEBO; TRAMADOL; UNINDEXED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ALLODYNIA; ARTICLE; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; HYPERALGESIA; HYPOCALCEMIA; INCIDENCE; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROTOXICITY; OPIOID INDUCED EMESIS; PAIN ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RADIOISOTOPE THERAPY; SEDATION; SIDE EFFECT; TERMINAL CARE; THROMBOCYTE FUNCTION; URINE RETENTION; VISUAL ANALOG SCALE; WORLD HEALTH ORGANIZATION;

EID: 80052727583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr390     Document Type: Article

References (75)

1. Frankish H. 15 million new cancer cases per year by 2020, says WHO. Lancet 2003; 361: 1278.
2. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-1449.
3. Deandrea S, Montanari M, Moja L et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985-1991.
4. Costantini M, Ripamonti C, Beccaro M et al. Prevalence, distress, management and relief of pain during the last three months of cancer patients' life. Results of an Italian mortality follow-back survey. Ann Oncol 2009; 20: 729-735.
5. Breivik H, Cherny N, Collett F et al. Cancer-related pain: a pan European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433.
6. Apolone G, Corli O, Caraceni A et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100: 1566-1574.
7. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-94.
8. Morselli M, Bandieri E, Zanin R et al. Pain and emotional distress in leukaemia patients at diagnosis. Leuk Res 2009; 34: e67-e68.
9. Higginson IJ, Murtagh F. Cancer pain epidemiology. In: Bruera E, Portenoy RK (eds). Cancer Pain. Assessment and Management. Vol. 3. Cambridge: Cambridge University Press, 2010; 37-52.
10. Portenoy RK, Koh M. Cancer pain syndromes. In: Bruera E, Portenoy RK (eds). Cancer Pain. Assessment and Management, Vol. 4. Cambridge: Cambridge University Press, 2010; 53-88.
11. Larue F, Colleau SM, Brasseur L, Cleeland CS. Multicentre study of cancer pain and its treatment in France. BMJ 1995; 310: 1034-1037.
12. Caraceni A, Cherny N, Fainsinger R et al. The Steering Committee of the EAPC Research Network. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
13. Kaasalainen S. Pain assessment in older adults with dementia using behavioural observation methods in clinical practice. J Gerontol Nurs 2007; 33: 6-10.
14. Gordon DB, Dahl JL, Miaskowski C et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005; 165: 1574-1580.
15. Van Herk R, van Dijk M, Baar FPM, Tibboel D, de Wit R. Observational scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res 2007; 56: 34-43.
16. American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002; 50: S205-S224.
17. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 2002; 24: 526-542.
18. Reid CM, Gooberman Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 2008; 19: 44-48.
19. De WitR, van Dam F, Zandbelt L et al. A pain education program for chronic cancer pain patients: follow-up results from a randomized controlled trial. Pain 1997; 73: 55-69.
20. World Health Organization. Cancer Pain Relief, 2nd edn. Geneva: World Health Organization, 1996.
21. National Comprehensive Cancer Network. (NCCN) Clinical Practice Guideline in Oncology. Adult Cancer Pain V.I. 2009.
22. Hanks GW, De Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-826.
23. Hanks GW, De Conno F, Cherny N et al. the Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain. Br J Cancer 2001; 84: 587-593.
24. Scottish Intercollegiate Guidelines Network. Control of Pain in Adults with Cancer. A National Clinical Guideline. SIGN-Scottish Intercollegiate Guidelines Network. November 2008.
25. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990; 41: 273-281.
26. Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain. Consensus Conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
27. Bruera E, MacMillian K, Kuehn N et al. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 1992; 49: 311-314.
28. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization, 1986.
29. Wallenstein S, Heidrich Gr, Kaiko R, Houde R. Clinical evaluation of mild analgesics: the measurement of clinical pain. Br J Clin Pharmacol 1980; 10 (Suppl 2): 319s-327s.
30. Littman G, Walker B, Schneider B. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Ther 1985; 38: 16-23.
31. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
32. Lussier D, Portenoy RK. Adjuvant analgesic drugs. In: Bruera E, Higginson IJ, Ripamonti C, von Gunten C (eds). Textbook of palliative medicine. London: Edward Arnold Publishers, 2006; 402-414.
33. Ripamonti C, Bandieri E. Cancer pain. Crit Rev Oncol Hematol 2009; 70: 145-149.
34. McNicol E, Strassels S, Gouds L, Lau J, Carr D. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (Cochrane Review). Cochrane Database Syst Rev 2009; 1: CD005180.
35. Stockler M, Vardy J, Pillai A, Warr D. Acetominophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004; 22: 3389-3394.
36. Joint Formulary Committee. British National Formulary. 55th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
37. European Medicines Agency. Public statement: European Medicines Agency announces regulatory action on COX-2 inhibitors (EMEA/62838/2005). Available from http://www.emea.europa.eu/pdfs/human/press/pr/6275705en.pdf.
38. Eisenberg E, Berkey C, Carr DB, Mosteller F, Chalmers C. Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756-2765.
39. Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment: Number 35 2001.
40. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 850-856.
41. Marinangeli F, Ciccozzi A, Leonardis M et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27: 409-416.
42. Maltoni M, Scarpi E, Modonesi C et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13: 888-894.
43. Mercadante S, Porzio G, Ferrera P et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006; 31: 242-247.
44. Cherny NI, Baselga J, De Conno F, Radrbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid policy initiative. Ann Oncol 2010; 21: 615-626.
45. Ripamonti C, Bareggi C. Pharmacology of opioid analgesia: clinical principles. In: Bruera E, Portenoy RK (eds). Cancer Pain. Assessment and Management, Vol.11. Cambridge: Cambridge University Press; 2010, 195-229.
46. Bandieri E, Chirarolanza A, Luppi M, Magrini N, Marata AM, Ripamonti C. Prescription of opioids in Italy: everything but the morphine. Ann Oncol 2009; 20: 961-962.
47. World Health Organization. Model List of Essential Drugs (EDL). Geneva: World Health Organization, 2007.
48. Hanks GW, Hoskin PJ, Aherne GW, Turner P, Poulain P. Explanation for potency of oral morphine on repeated dosage? Lancet 1987; ii: 723-725.
49. Kaiko RF. The therapeutic equivalence of IM and PO administration of morphine-1:3 or 1:6. J Palliat Care 1988; 4: 64-66.
50. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639-664.
51. Zech DFJ, Grond S, Lynch J et al. Validation of the World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63: 65-76.
52. Myers J, Chan V, Jarvis V, Walker-Dilks C. Intraspinal techniques for pain. management in cancer patients: a systematic review. Support Care Cancer 2010; 18: 137-149.
53. Smith TJ, Staats PS, Deer T et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20: 4040-4049.
54. Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 1996; 67: 443-449.
55. Ripamonti C, Brunelli C. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2003; 21: 2801-2802.
56. Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006; 20: s17-s23.
57. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
58. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304-315.
59. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003; 17: 248-256.
60. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine. An evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
61. McQuay HJ, Collins S, Carroll D et al. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2008; 2: CD001793.
62. Roque M, Martinez-Zapata M, Alonso-Coello P et al. Radioisotopes for metastatic bone pain (Cochrane Review). Cochrane Database Syst Rev 2006.
63. Sciuto R, Festa A, Pasqualoni R et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HeDP in breast cancer patients. Breast Canc Res Treat 2001; 66: 101-109.
64. Leondi AH, Souvatzoglou MA, Rapti AS et al. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HeDP in patients with lung cancer. J Nucl Med 2004; 48: 211-219.
65. Han SH, de Klerk JM, Tan S et al. The PLACORHeN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43: 1150-1156.
66. Wog R, Wiffen PJ. Bisphosphonates for relief of pain secondary to bone metastases. Cochrane Syst Rev 2002; 2: CD002068.
67. Ripamonti C, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaws (ONJs) after implementation of dental preventive measure in solid tumours treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Italy. Ann Oncol 2009; 20: 137-145.
68. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-120.
69. Tan P, Barry S, Reken S et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010; 340: c1079.
70. Saarto T, Wiffen P. Antidepressants for neuropathic pain (Cochrane Review). Cochrane Syst Rev 2007; 2: CD002068.
71. Wiffen P, Mcquay H, Edwards J, Moore R. Gabapentin for acute and chronic pain (Cochrane Review). Cochrane Syst Rev 2005; 3: CD005452.
72. Wiffen P, Collins S, Mcquay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). Cochrane Syst Rev 2005; 3: CD001133.
73. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Syst Rev 2005; 3: CD003345.
74. Bruera E, MacMillan K, Hanson J. Palliative care in a cancer center: results in 1984 versus 1987. J Pain Symptom Manage 1990; 5: 1-5.
75. Cherny NJ, Chang V, Frager G et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283-1293.